Loss of SYNCRIP Unleashes APOBEC-Driven Mutagenesis, Tumor Heterogeneity, and AR-Targeted Therapy Resistance in Prostate Cancer

The authors identified synaptotagmin-binding cytoplasmic RNA-interacting protein (SYNCRIP) as an endogenous molecular brake which suppressed APOBEC-driven mutagenesis in prostate cancer.